PMID: 9656970Jul 10, 1998Paper

Diabetic nephropathy

Disease-a-month : DM
S M Kobrin

Abstract

Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) and accounts for 35% of the ESRD population in the United States. It results in considerable morbidity, mortality, and expense. The average cost of managing one diabetic patient with ESRD is approximately $50,000 a year. Over the last decade, several advances in the management of diabetic nephropathy have allowed physicians to intervene and retard the progression of renal failure in patients with diabetic nephropathy. Stalling the progression of renal failure allows patients to maintain a superior quality of life and saves society millions of dollars that can be allocated to other aspects of health care. The prevalence of diabetes mellitus continues to increase. With the continued advances in medical technology and care, persons with this disease will live longer, and the incidence of diabetic nephropathy will increase. Primary care physicians will have the most frequent contact with these patients and therefore will have the greatest potential to favorably affect their clinical course. This review focuses on the therapeutic interventions available to delay the progression of diabetic nephropathy. Clinicians should strive to secure euglycemia and ob...Continue Reading

References

Aug 1, 1992·Journal of the American Society of Nephrology : JASN·K SchmidtG E Striker
Dec 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J A Breyer
Dec 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R W Schrier, S Savage
Apr 1, 1992·Kidney International·J BarzilayA S Krolewski
Sep 19, 1991·The New England Journal of Medicine·Z MakitaH Vlassara
Oct 18, 1990·The New England Journal of Medicine·D M Wilson, J A Luetscher
Dec 15, 1990·Annals of Internal Medicine·B K Demarie, G L Bakris
Oct 1, 1989·Kidney International·S AndersonB M Brenner
Jun 6, 1987·British Medical Journal·H H ParvingP A Svendsen
Nov 1, 1986·Clinics in Endocrinology and Metabolism·A Grenfell, P J Watkins
Jul 12, 1984·The New England Journal of Medicine·C E Mogensen, C K Christensen
Jul 1, 1995·Diabetes·P RossingH H Parving
Feb 1, 1994·Diabetes Care·P T SawickiM Berger
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Mar 1, 1997·Journal of the American Society of Nephrology : JASN·H N Ibrahim, T H Hostetter

❮ Previous
Next ❯

Citations

Jun 8, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·R Lehmann, E D Schleicher
Nov 30, 2000·Western Journal of Nursing Research·D K HathawayA O Gaber
Jan 1, 2008·Nutrition Research and Practice·Ju-Hyun ChoWha-Young Kim
Mar 10, 2001·The Journal of Nutrition·J S SternA T Borchers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.